ArticleSensors (Basel, Switzerland)2023
A Novel Approach for Brain Tumor Classification Using an Ensemble of Deep and Hand-Crafted Features.
Article in Sensors (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 46 citations in OpenAlex.
- Chitosan-Based Nanoparticles for Nose-to-Brain Drug Delivery: A Real Path toward Effective CNS Therapy?ACS biomaterials science & engineering · 2026Review
- Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances.Military Medical Research · 2026Review
- Prediction of early recurrence of adult-type diffuse gliomas following radiotherapy using multi-modal magnetic resonance images.Medical physics · 2024Article
- Deep Learning Technology and Image Sensing.Sensors (Basel, Switzerland) · 2024Article
- Comparison of machine learning algorithms for the classification of spinal cord tumor.Irish journal of medical science · 2024Article
- Advances in the Use of Deep Learning for the Analysis of Magnetic Resonance Image in Neuro-Oncology.Cancers · 2024Review
- BrainCDNet: a concatenated deep neural network for the detection of brain tumors from MRI images.Frontiers in human neuroscience · 2024Article
- Enhanced MRI-based brain tumour classification with a novel Pix2pix generative adversarial network augmentation framework.Brain communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
One of the most severe types of cancer caused by the uncontrollable proliferation of brain cells inside the skull is brain tumors. Hence, a fast and accurate tumor detection method is critical for the patient's health. Many automated artificial intelligence (AI) methods have recently been developed to diagnose tumors. These approaches, however, result in poor performance; hence, there is a need for an efficient technique to perform precise diagnoses. This paper suggests a novel approach for brain tumor detection via an ensemble of deep and hand-crafted feature vectors (FV). The novel FV is an ensemble of hand-crafted features based on the GLCM (gray level co-occurrence matrix) and in-depth features based on VGG16. The novel FV contains robust features compared to independent vectors, which improve the suggested method's discriminating capabilities. The proposed FV is then classified using SVM or support vector machines and the k-nearest neighbor classifier (KNN). The framework achieved the highest accuracy of 99% on the ensemble FV. The results indicate the reliability and efficacy of the proposed methodology; hence, radiologists can use it to detect brain tumors through MRI (magnetic resonance imaging). The results show the robustness of the proposed method and can be deployed in the real environment to detect brain tumors from MRI images accurately. In addition, the performance of our model was validated via cross-tabulated data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.